2026-03-06 01:30Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [4] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [4] - R&D expenses for 2025 were $148 million, lower than 2024 as many late-stage trials were nearing completion [4] Business Line Data and Key Metrics Changes - Ex-China FRUZAQLA sales grew by 26% year-over-year, totaling $366 million in in-market sales [2] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [2] - ORPATHYS and Surufatinib accounted for 11% of total 2025 EMARC sales but faced competition, impacting their performance [9] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds due to Medicare Part D redesign, impacting overall performance [8] - In China, ELUNATE experienced a decline of 13% in the first half but rebounded with 33% growth in the second half [8] - The ITP market potential in China is significant, with over 250,000 actively treated patients, representing a market of $500 million to $700 million [18] Company Strategy and Development Direction - The company aims to accelerate global development of its ATTC programs and explore potential in-licensing and M&A opportunities [3] - A focus on building a strong hematology portfolio is evident, with the launch of the first-in-class treatment for EZH2 mutation and follicular lymphoma [10] - The company is committed to maintaining a balance between R&D investments and commercial income generation [50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with multiple potential NDA filings and expected growth from new hematology products [24] - The oncology revenue guidance for 2026 is projected between $330 million and $450 million, reflecting strong growth expectations [5] - Management acknowledged the challenges faced in the U.S. market but highlighted the continued expansion of FRUZAQLA in other countries [70] Other Important Information - The company has a strong cash position of approximately $1.4 billion, allowing for accelerated investments in ATTC development [3] - The ATTC platform is designed to reduce toxicities by delivering payloads directly to tumors, targeting a significant market across various cancer types [20] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong growth expectations, particularly from new indications and recovery momentum [28][29] Question: Why was the SAFFRON readout delayed? - The SAFFRON readout is now expected in mid-2026 [30] Question: What is the indication for the ATTC platform candidates? - The first candidate, HMPL-A251, is currently enrolling HER2 expressing solid tumor patients, focusing on post-HER2 treatment settings [30] Question: How do you expect the changes in Medicare Part D to impact sales? - Management noted that while there were impacts in 2025, they anticipate continued growth in the U.S. and other markets [70] Question: What is the strategy for the ATTC platform? - The company is considering potential licensing out of some programs while maintaining control over others to maximize long-term value [46]